Vicor Technologies, Inc. (OTCBB: VCRT) Experienced Management Continues to Pay Off

Written by admin on March 17, 2010

Vicor Technologies, Inc. (OTCBB: VCRT)

With the latest press release we are face to face with the benefits of experienced management in terms of the business side of science.

We know a large physician shareholder base represents the early adoptees of this Company.

In anticipation of the product launch in early 2010, Vicor identified several of the Company’s physician shareholders and their practices for early adoption of the PD2i Analyzer™.  The goal was to obtain crucial feedback. Physician acceptance is a critical success factor.  This week press release indicates this crucial information:

The PD2i Analyzer™ is being well received among physicians.

This is great news and a tremendous reflection on management.

The Company’s strategy has always been to establish a large physician base – 350 shareholders and 450 members of the Company’s National Cardiac Panel – as early adopters of the Company’s technology to ensure that:

  • The product is well received by physicians interested in Vicor’s success
  • Product enhancement suggestions provided by these early adopters can be incorporated into the technology before a national rollout.

The Company’s recent press release indicates EXPERIENCED LEADERSHIP HAS PAID OFF.

Vicor indicated the Company continues to execute their business plan for ongoing marketing efforts and sales of the PD2i Analyzer™, which is being well received among physicians.

Vicor is also on target for the completion of clinical efforts directed at additional 510(k) submissions, which should lead to an acceleration of marketing efforts once granted.

Access to an archive of analyzable data such as that provided by the MUSIC Trial — which is fairly uncommon — provided Vicor with the tremendous opportunity to quickly and cost-effectively produce a dataset, which is believed will be of sufficient statistical significance to support an application for sudden cardiac death in a claim to the FDA for 510(k) marketing clearance.

Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise.

Vicor’s Three Products Employing the PD2i™ Nonlinear Algorithm.

  • PD2i Analyzer(TM) has FDA 510(k) marketing clearance. It measures Heart Rate Variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes.
  • PD2i VS(TM) (Vital Sign) stratifies risk in combat and civilian trauma victims and is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. (http://www.usaisr.amedd.army.mil/)
  • PD2i CA(TM) (Cardiac Analyzer) identifies patients at risk of sudden cardiac death and is in multiple clinical trials.

Vicor Technologies, Inc.
2300 NW Corporate Blvd.
Suite 123
Boca Raton, FL 33431
877.528-PD2i (7324)
info@vicortech.com

Disclaimer and Forward-Looking Statements
The appearance of name-brand institutions or products in this profile does not constitute endorsement by the U.S. Army Institute of Surgical Research, the U.S. Army Medical Research and Materiel Command, the Department of the Army, Department of Defense or the U.S. Government of the information, products or services contained therein.

Forward-looking statements in this profile are based on current plans and expectations that are subject to uncertainties and risks, which could cause the Company’s future results to differ materially. The following factors, among others, could cause the Company’s actual results to differ: the Company’s ability to obtain FDA approval of the PD2i VS™ (Vital Sign) for military and civilian applications and the PD2i CA™ (Cardiac Analyzer), the Company’s ability to continue to receive financing sufficient to continue operations and complete the critical clinical trials; the Company’s ability to continue as a going concern; the Company’s ability to successfully develop products based on the Company’s technologies, included but not limited to the Company’s ASP distribution model for the PD2i Analyzer™; the Company’s ability to obtain and maintain adequate levels of third-party reimbursement for the Company’s products; the impact of competitive products and pricing; the Company’s ability to receive regulatory approval for the Company’s products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for the Company’s technologies; the ability of third-party manufacturers to manufacture the Company’s products; the Company’s ability to retain the services of the Company’s key personnel; the Company’s ability to market and sell the Company’s products successfully; the Company’s ability to protect the Company’s intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and Vicor assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.